CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths globally.Immune checkpoint blockade (ICB) Beta Sitosterol has transformed cancer medicine, with anti-programmed cell death protein 1 (anti-PD-1) therapy now well-utilized for treating NSCLC.Still, not all patients with NSCLC respond positively to anti-PD-1 therapy,